基因癌症生物標記市場：現況分析與預測（2023-2030）

Genetic Cancer Biomarker Market: Current Analysis and Forecast (2023-2030)

出版日期: 2023年12月30日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

遺傳癌症生物標記是 DNA 中的特定變化，可以顯示癌症的風險增加或預測特定癌症的表現。這些生物標記透過識別與各種癌症相關的基因突變和變化，在早期檢測、個人化治療計劃和預後評估中發揮重要作用。其他幾個因素正在全球推動遺傳癌症生物標記的發展，包括遺傳疾病和不健康生活方式的增加。例如，根據BMC Public Health 的數據，2023 年7 月不健康生活方式的盛行率為：飲食為86.4%，飲酒為14.5%，菸草為6.0%，體力活動為72.2%，螢幕時間為42.3%，睡眠時間為63.9% 。

由於全球酒精和菸草盛行率不斷上升，遺傳癌症生物標記市場預計將以約 18.4% 的速度穩定成長。根據 2021 年全國藥物使用與健康調查 (NSDUH)，2020 年有 2,950 萬名 12 歲及以上的人患有酒精使用障礙 (AUD)。在預測期內，有幾個因素正在推動市場成長，包括癌症發病率的急劇上升、對喉癌的認識不斷提高、吸煙人口的增加、酗酒文化的興起以及腫瘤學投資的增加。我們正在推動它。除此之外，透過遺傳癌症生物標記物提高治療效率可以加快治療過程並提高準確性，這也穩步推動了遺傳癌症生物標記市場的發展。例如，根據《美國癌症協會雜誌》報道，2021 年美國報告了 1,898,160 例新癌症病例和 608,570 例癌症死亡病例。

依癌症類型，市場分為乳癌、攝護腺癌、白血病等。 2022年全球基因癌症生物標記市場中，乳癌領域佔最大份額。由於延遲懷孕、肥胖病例增加、老年人口增加以及吸煙、酗酒等不健康生活習慣的流行，該細分市場佔據了市場主導地位。乳癌家族史也是這一細分市場的驅動因素。例如，根據世界衛生組織（WHO）的數據，2020年，全球有230萬名女性被診斷出罹患乳癌，其中68.5萬人死亡。因此，在癌症類型中，乳癌領域在2022年佔據主要市場份額。

依科技分為組學、生物資訊學等。由於其在很短的時間內提供大量數據的潛在特點，預計 OMICS 行業將在預測期內佔據重要的市場份額。組學技術專注於四大組學：基因組學、轉錄組學、蛋白質組學、代謝組學及其表觀組學。該領域是由不斷進步的技術推動的。例如，2023 年 4 月，Biomodal（原名 Cambridge Epigenetix）宣布了一種新的二重多組學解決方案，該解決方案揭示了將單個小樣本中的遺傳和表觀遺傳信息結合起來的能力。因此，在技術中，組學類別預計在預測期內表現出更高的複合年增長率。

為了更了解遺傳癌症生物標記的市場介紹，市場為北美（美國、加拿大等北美地區）、歐洲（德國、英國、法國、西班牙、義大利等歐洲地區）、亞太地區（中國、日本、印度、亞太地區其他地區）及世界其他地區。在目前的 2022 年情境中，由於煙霧污染加劇、酒精消費增加以及開發有效遺傳癌症生物標記的投資增加，北美將主導市場。政府機構已啟動喉癌宣傳計劃，為患者提供有效的護理。例如，2023年7月，美國癌症研究協會和美國頭頸學會在蒙特婁舉辦了第三屆AACR-AHNS頭頸癌聯合會議，展示了最新的研究成果，並提供了生物學、檢測、影像、預防、治療等。 AACR 也向進行與頭頸癌相關的有前景研究的研究人員提供研究資助。因此，按地區劃分，北美將在 2022 年佔據較大市場份額。

Genetic cancer biomarkers are specific changes in DNA that can indicate an increased risk of developing cancer or predict how a particular cancer might behave. These biomarkers play a crucial role in early detection, personalized treatment plans, and assessing prognosis by identifying genetic mutations or alterations associated with different types of cancer. Several other factors, such as rising genetic disorders and unhealthy lifestyles are leading drivers of genetic cancer biomarkers globally. For instance, according to the BMC Public Health, in July 2023, the prevalence of unhealthy lifestyles was 86.4% for diet, 14.5% for alcohol, 6.0% for tobacco, 72.2% for physical activity, 42.3% for screen time, and 63.9% for sleep duration.

The Genetic Cancer Biomarker Market is expected to grow at a steady rate of around 18.4% owing to the increased prevalence of alcohol and tobacco globally. According to the 2021 National Survey on Drug Use and Health (NSDUH), 29.5 million people ages 12 and older had Alcohol Use Disorder (AUD) in the year 2020. Several factors, including a surge in the incidence of cancer, increasing awareness regarding throat cancer, increasing smoking population, rising alcoholism culture, and increased investments in oncology departments are driving the growth of the market during the forecast period. Apart from this, accelerated treatment efficiency with genetic cancer biomarkers has resulted in faster treatment procedures and better accuracy which is also driving this market of genetic cancer biomarkers at a steady rate. For instance, according to the American Cancer Society Journals in 2021, 1,898,160 new cancer cases and 608,570 cancer deaths were reported in the U.S.

Based on cancer type, the market is segmented into breast, prostate, leukemia, and others. The breast cancer segment held the maximum share in the global market of genetic cancer biomarkers in 2022. This segment dominated the market because of the delayed pregnancies, rising cases of obesity, increasing geriatric population, and increased prevalence of ill lifestyles including smoking, alcoholism, and unhealthy lifestyles among people. A family history of breast cancer is also a propelling factor for this segment. For instance, according to the World Health Organization in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. Thus, amongst cancer types, the breast cancer segment held a significant share of the market in 2022.

Based on technology, the market is categorized into OMICS, bioinformatics, and others. The OMICS segment is expected to hold a significant share of the market in the forecast period owing to its potential feature of providing a huge amount of data in a very short period. OMICS technology focuses on the four big omics, i.e., genomics, transcriptomics, proteomics, and metabolics, and their epiomics. This segment is propelled by rising technological advancements. For instance, in April 2023, Biomodal, formerly known as Cambridge Epigenetix, launched its new duet multiomics solution, which reveals the combinatorial power of genetic and epigenetic information from a single low-volume sample. Thus, amongst technology, the OMICS category is expected to witness higher CAGR during the forecast period.

For a better understanding of the market adoption of genetic cancer biomarkers, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the increasing smoke pollution, increasing alcohol consumption, and rising number of investments in developing effective genetic cancer biomarkers. Government organizations are initiating throat cancer awareness programs to provide efficient care to patients. For example, In July 2023, the American Association for Cancer Research and the American Head and Neck Society organized the third AACR-AHNS Joint Conference on Head and Neck Cancer in Montreal to present their latest research and provide critical updates on head and neck cancer biology, detection, imaging, prevention, and therapy, among other topics. The AACR also awards research grants to investigators pursuing promising research related to head and neck cancer. Thus, amongst regions, North America held a significant share of the market in 2022.

Some of the major players operating in the market include: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; QIAGEN N.V.; Illumina Inc.; Bio-Rad Laboratories Inc.; Exact Sciences; Merck KGaA; Pfizer Inc.; Seegene Technologies Inc.; Siemens Healthineers.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Genetic Cancer Biomarker Market
2.2. Research Methodology of the Genetic Cancer Biomarker Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE GENETIC CANCER BIOMARKER MARKET

6 GENETIC CANCER BIOMARKER MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY CANCER TYPE

7.1. Breast Cancer
7.2. Prostate Cancer
7.3. Leukemia Cancer
7.4. Others

8 MARKET INSIGHTS BY TECHNOLOGY

8.1. OMICS
8.2. Bioinformatics
8.3. Others

9 MARKET INSIGHTS BY REGION

9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
9.4. Rest of World